Scarica l'app Stockscreener
3.72
1.09%
0.04
Aquestive Therapeutics Inc Borsa (AQST) Ultime notizie
Aquestive gains as allergy therapy undergoes FDA review - MSN
BRIEF—FDA accepts NDA for Aquestive’s Anaphylm - The Pharma Letter
AQST: HC Wainwright & Co. Reiterates Buy Rating for Aquestive Therapeutics | AQST Stock News - GuruFocus
Aquestive stock gains on FDA review for allergy drug (AQST) - Seeking Alpha
Aquestive Gets FDA Acceptance of New Drug Application for Severe Allergic Reaction Treatment - MarketScreener
AQST Stock: FDA Accepts NDA for Anaphylm to Treat Severe Allergic Reactions | AQST Stock News - GuruFocus
FDA accepts Aquestive’s NDA for oral epinephrine film with 2026 target date - Investing.com Canada
Aquestive Therapeutics Announces FDA Acceptance of New Drug - GlobeNewswire
Revolutionary Needle-Free Epinephrine Treatment Advances: FDA Sets 2026 Decision Date for Oral Anaphylaxis Drug - Stock Titan
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of “Buy” by Analysts - Defense World
Research Analysts Offer Predictions for AQST FY2026 Earnings - Defense World
Aquestive Therapeutics Holds Annual Stockholders Meeting - TipRanks
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Millennium Management LLC - Defense World
Two Sigma Advisers LP Takes $57,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Two Sigma Investments LP Buys 42,160 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share (NASDAQ:AQST) - Seeking Alpha
Jane Street Group LLC Sells 44,603 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Wellington Management Group LLP Sells 5,579 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
BNP Paribas Financial Markets Sells 7,286 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stake Lifted by ProShare Advisors LLC - Defense World
Oppenheimer Begins Coverage on Aquestive Therapeutics (NASDAQ:AQST) - Defense World
Aquestive Therapeutics (NASDAQ:AQST) Earns Outperform Rating from Analysts at Oppenheimer - Defense World
Aquestive Therapeutics (NASDAQ:AQST) Coverage Initiated at Oppenheimer - Defense World
Oppenheimer Initiates Coverage on Aquestive Therapeutics (NASDAQ:AQST) - Defense World
Aquestive Therapeutics (NASDAQ:AQST) Now Covered by Analysts at Oppenheimer - Defense World
Aquestive Therapeutics (AQST) Receives Positive Coverage and Sets Future Milestones | AQST Stock News - GuruFocus
Deutsche Bank AG Grows Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics (NASDAQ:AQST) Now Covered by Oppenheimer - Defense World
Aquestive Therapeutics Prepares for FDA Approvals and Launches - TipRanks
AQST: Oppenheimer Lowers Price Target for Aquestive Therapeutics - GuruFocus
AQST: Oppenheimer Lowers Price Target for Aquestive Therapeutics | AQST Stock News - GuruFocus
Oppenheimer lowers Aquestive Therapeutics stock price target to $7 By Investing.com - Investing.com Canada
Oppenheimer Adjusts Price Target for Aquestive Therapeutics (AQST) | AQST Stock News - GuruFocus
Bank of America Corp DE Boosts Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
D. E. Shaw & Co. Inc. Has $450,000 Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Those who invested in Aquestive Therapeutics (NASDAQ:AQST) three years ago are up 128% - Yahoo
Northern Trust Corp Has $2.14 Million Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential - Insider Monkey
13 Best Multibagger Stocks to Invest in Now - Insider Monkey
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of “Buy” by Analysts - Defense World
Q2 EPS Forecast for Aquestive Therapeutics Cut by Analyst - Defense World
AQST FY2025 EPS Estimate Lowered by Cantor Fitzgerald - Defense World
Q2 Earnings Forecast for AQST Issued By Leerink Partnrs - Defense World
HC Wainwright Reaffirms Buy Rating for Aquestive Therapeutics (NASDAQ:AQST) - Defense World
Aquestive Therapeutics targets $44M–$50M revenue in 2025 as Anaphylm launch preparations accelerate - MSN
Analysts Have Lowered Expectations For Aquestive Therapeutics, Inc. (NASDAQ:AQST) After Its Latest Results - simplywall.st
Aquestive Therapeutics’ Earnings Call: Mixed Outlook - TipRanks
AQST: Aquestive Therapeutics Receives Continued "Buy" Rating from HC Wainwright | AQST Stock News - GuruFocus
Lake Street Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST) - The Globe and Mail
AQST: Aquestive Therapeutics Receives Continued "Buy" Rating fro - GuruFocus
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates - MSN
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2025 Earnings Call Transcript - Insider Monkey
Aquestive Therapeutics’ Q1 2025: Focus on Anaphylm - TipRanks
Earnings call transcript: Aquestive’s Q1 2025 earnings miss, stock drops 7% By Investing.com - Investing.com Nigeria
AQST Price Target Reduced by Piper Sandler | AQST Stock News - GuruFocus
Aquestive (AQST) Reports Lower Q1 Revenue, Focuses on Anaphylm L - GuruFocus
Aquestive Therapeutics (AQST) Anticipates FDA Milestone for Anap - GuruFocus
0.54%
1.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):